Has Jonathan Tobis, MD received payments from drug or device companies?

Yes. Drug and device makers reported $76,769 in general payments to Jonathan Tobis, MD across 101 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jonathan Tobis, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jonathan Tobis, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jonathan Tobis, MD

Cardiovascular Disease · Los Angeles, CANPI 1811917073

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $52,595 of the $76,769 with a category attached, or 68.5%. W. L. Gore & Associates, Inc. accounts for 96.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $26,427 and has fallen 98.7% since, to $354 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$76,769in general payments, 2019–2025

Across 101 payments — averaging $760.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

W. L. Gore & Associates, Inc.$74K
Abbott$1K
Penumbra, Inc.$384
Edwards Lifesciences$183
Shockwave Medical, Inc$173
Boston Scientific$166
plus $521 from 5 others

$38,299in research payments, 2019–2025

Across 6 payments — averaging $6383.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

W. L. Gore & Associates, Inc.$38K

What the payments were for

Consulting fees$52,59569%
Speaking & faculty fees$13,45018%
Travel & lodging$6,9319%
Food & beverage$3,7935%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
W. L. Gore & Associates, Inc.	75	$74,120
Abbott	14	$1,222
Penumbra, Inc.	2	$384
Edwards Lifesciences	3	$183
Shockwave Medical, Inc	1	$173
Boston Scientific	1	$166
Abiomed	1	$145
E.r. Squibb & Sons, L.L.C.	1	$125
Lexicon Pharmaceuticals, Inc.	1	$121
AstraZeneca	1	$120
Cook Medical LLC	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,769 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California →

Medicare billing

Part B allowed, 2024

$25,064

Medicare patients

Services billed

144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	52	$61,361
Praluent PenAlirocumab	11	$15,725
LanoxinDigoxin	11	$3,027
Rosuvastatin Calcium	73	$1,434
Chlorthalidone	49	$916
Ezetimibe	40	$865
Nitroglycerin	13	$601
Losartan Potassium	36	$353
Propranolol Hcl	16	$349
Atorvastatin Calcium	52	$341
Spironolactone	13	$278
ClopidogrelClopidogrel Bisulfate	22	$252
Lisinopril	17	$116
Furosemide	11	$37
Amoxicillin	15	$36

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Los Angeles

Cathleen Bairey-MerzLos Angeles$1.2M
Karol WatsonLos Angeles$553K
Jamil AboulhosnLos Angeles$423K
Darren BermanLos Angeles$392K
Arash NayeriLos Angeles$281K
Gregg FonarowLos Angeles$260K
Martha GulatiLos Angeles$141K
Ted LoveHillsborough$102.8M
Paul KurthSanta Barbara$6.1M
Jason RogersSacramento$4.4M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →